Abstract RUNX2 is a multifunctional transcription factor that controls skeletal development by regulating the differentiation of chondrocytes and osteoblasts and the expression of many extracellular matrix protein genes during chondrocyte and osteoblast differentiation. This transcription factor plays a major role at the late stage of chondrocyte differentiation: it is required for chondrocyte maturation and regulates Col10a1 expression in hypertrophic chondrocytes and the expression of Spp1, Ibsp, and Mmp13 in terminal hypertrophic chondrocytes. It is essential for the commitment of pluripotent mesenchymal cells to the osteoblast lineage. During osteoblast differentiation, RUNX2 upregulates the expression of bone matrix protein genes including Col1a1, Spp1, Ibsp, Bglap, and Fn1 in vitro and activates many promoters including those of Col1a1, Col1a2, Spp1, Bglap, and Mmp13. However, overexpression of Runx2 inhibits osteoblast maturation and reduces Col1a1 and Bglap expression. The inhibition of RUNX2 in mature osteoblasts does not reduce the expression of Col1a1 and Bglap in mice. Thus, RUNX2 directs pluripotent mesenchymal cells to the osteoblast lineage, triggers the expression of major bone matrix protein genes, and keeps the osteoblasts in an immature stage, but does not play a major role in the maintenance of the expression of Col1a1 or Bglap in mature osteoblasts. During bone development, RUNX2 induces osteoblast differentiation and increases the number of immature osteoblasts, which form immature bone, whereas Runx2 expression has to be downregulated for differentiation into mature osteoblasts, which form mature bone. During dentinogenesis, Runx2 expression is downregulated, and RUNX2 inhibits the terminal differentiation of odontoblasts.
Introduction
The vertebrate skeleton is composed of cartilage and bone. Bone is formed through either intramembranous or endochondral ossification. Osteoblasts directly form intramembranous bones, whereas chondrocytes first form a cartilaginous skeleton that is then replaced with bone by osteoblasts and osteoclasts through the process of endochondral ossification. In chrondocyte differentiation, after mesenchymal condensation, pluripotent mesenchymal cells differentiate into immature chondrocytes, which produce type II collagen and proteoglycan. The immature chondrocytes further differentiate into hypertrophic chondrocytes, which express Col10a1, and finally become terminal hypertrophic chondrocytes, which express Spp1 (secreted phophoprotein 1/osteopontin), Ibsp (integrin-binding sialoprotein/bone sialoprotein II), and Mmp13 (matrix metallopeptidase 13) (Marks and Odgren 2002; Inada et al. 1999) .
These processes in chondrocyte differentation are regulated by many factors, and specific transcription factors play essential roles in the differentiation of chondrocytes. The transcription factor SOX9 plays a crucial role in mesenchymal condensation, leading to the formation of the cartilaginous template, whereas SOX9, SOX5, and SOX6 are required for the production of cartilaginous matrix, and runt-related transcription factor 2 (RUNX2)/ core-binding factor α1 (CBFA1)/polyoma-enhancerbinding protein 2αA (PEBP2αA) has an important function in the terminal diffrentiation of chondrocytes, a function that is a prerequisite for endochondral ossification. RUNX3, which is another Runx family transcription factor, is also involved in the terminal differentiation of chondrocytes (Komori 2005) (Fig. 1) .
During osteoblast differentiation, RUNX2, SP7, and canonical Wnt signaling play essential roles in the commitment of pluripotent mesenchymal cells to the osteoblastic lineage (Komori 2006) . After commitment into the osteoblastic lineage, the osteoblasts express bone matrix protein genes at various expression levels depending on the maturation level of the cells. Immature mesenchymal cells and preosteoblasts weakly express Col1a1, and its expression is upregulated in immature osteoblasts (Aubin and Triffitt 2002; Inada et al. 1999) . Immature osteoblasts express Spp1 and then Ibsp, and maturated osteoblasts strongly express Bglap (bone gamma-carboxyglutamate [gla] protein/ osteocalcin) (Aubin and Triffitt 2002; Maruyama et al. 2007) . Mature osteoblasts are embedded into the bone matrix and finally become osteocytes, which express Dmp1 (dentin matrix protein 1) (Fig. 2) .
Expression of Runx2 during skeletal development
RUNX2 is expressed as two isoforms that possess different Ntermini (type I RUNX2 starting with the sequence MRIPVand type II RUNX2 starting with the sequence MASNS) and that are expressed under different promoters (Komori and Kishimoto 1998) . Both type I and type II Runx2 mRNAs are expressed in chondrocytes and osteoblasts, although type II Runx2 mRNA is predominantly expressed in osteoblasts (Enomoto et al. 2000; Banerjee et al. 2001; Choi et al. 2002) . The two isoforms have similar functions but differ in their dependency on CBFB, which is an essential co-transcription factor of RUNX2 (Kundu et al. 2002; Miller et al. 2002; Yoshida et al. 2002; Kanatani et al. 2006) .
During skeletal development, both type I and type II Runx2 mRNAs are weakly expressed in proliferating chondrocytes, their expression is upregulated as chondrocytes differentiate, and both type I and type II Runx2 mRNAs are highly expressed in chondrocytes with maturational stages ranging from prehypertrophic to hypertrophic chondrocytes (Simeone et al. 1995; Kim et al. 1999; Enomoto et al. 2000; Inada et al. 1999; Stricker et al. 2002) . During the progression of osteoblast differentiation, the expression of Runx2 mRNA and RUNX2 protein dynamically change, and the expression of Spp1 (SPP1) and Bglap (BGLAP) can be used to highlight this dynamic process. During the development of intramembranous bones, RUNX2 is strongly detected in preosteoblasts, immature osteoblasts, and early mature osteoblasts. At 1 week of age in wild-type mice, preosteoblasts in the periosteum of the mandible express RUNX2 but not SPP1 or BGLAP, whereas inside the mandible, both SPP1-positive immature osteoblasts and BGLAP-positive early mature osteoblasts express RUNX2 (Maruyama et al. 2007) . During the development of endochondral bones, RUNX2 is first detected in mesenchymal cells in the perichondrial region: in the femur at 1 week of age, the preosteoblasts in the perichondrial region surrounding proliferating and prehypertrophic chondrocytes express RUNX2 but not SPP1 or BGLAP; immature osteoblasts surrounding the hypertrophic chondrocyte layer express RUNX2 and SPP1 but not BGLAP; and BGLAP-positive early mature osteoblasts, which express RUNX2, appear in the metaphyseal cortical bone (Maruyama et al. 2007) . During long bone development, osteoblasts at the metaphysis are less mature than those at the diaphysis: in the femur at 4 weeks of age, SPP1-positive immature osteoblasts strongly express RUNX2 and BGLAP-positive mature osteoblasts weakly express RUNX2 in the metaphysis, whereas RUNX2 and SPP1 are undetectable by immunohistochemistry in most of the BGLAP-positive late mature osteoblasts in the diaphysis even though the mRNAs of Runx2 and Spp1 are detectable by in situ hybridization (Maruyama et al. 2007 ). Thus, RUNX2 is expressed in preosteoblasts, which do not express SPP1 or BGLAP, is strongly expressed in SPP1-positive immature osteoblasts, and then is expressed in BGLAP-positive early mature osteoblasts, but RUNX2 expression is finally downregulated in BGLAP-positive late mature osteoblasts (Maruyama et al. 2007) (Fig. 2) .
RUNX2 regulates the expression of extracellular matrix protein genes in chondrocytes
During chondrocyte maturation, immature chondrocytes express Col2a1, mature chondrocytes (hypertrophic chondrocytes) express Col10a1, and terminally differentiated chondrocytes (terminal hypertrophic chondrocytes) express Spp1 and Ibsp. Runx2-deficient (Runx2 −/− ) mice completely lack bone formation because of the absence of osteoblasts (Komori et al. 1997; Otto et al. 1997) . The skeleton of Runx2 −/− mice is composed of cartilage, chondrocyte maturation is inhibited in Runx2 −/− mice, and the expression of Col10a1 in hypertrophic chondrocytes is drastically reduced (Inada et al. 1999; Kim et al. 1999) . In restricted skeletons, including the tibia, fibula, radius, and ulna, however, chondrocytes maturate to terminal hypertrophic chondrocytes. In these skeletons, Col10a1 is detected, whereas Spp1, Ibsp, and Mmp13, which are expressed in terminal hypertrophic chondrocytes, are undetectable. RUNX2 directly regulates the expression of Spp1 in a synergistic manner with ETS1 (Sato et al. 1998 ). Runx2 also directly regulates Mmp13 expression, and RUNX2, which is activated by protein kinase A, and AP1 physically interact and are required for parathyroid-hormone-dependent Mmp13 expression (Jiménez et al. 1999; Porte et al. 1999; Selvamurugan et al. 2000; Hess et al. 2001) (Fig. 1) . MMP13, which efficiently degrades the native helix of fibrillar collagen with preferential activity on type II collagen and is able to degrade aggrecan, plays an important role in the degradation of cartilage matrix at the chondro-osseous junction in the process of endochondral ossification (Fosang et al. 1996; Knäuper et al. 1996; Inada et al. 2004 ). Overexpression of Runx2 in chondrocytes under the control of the Col2a1 promoter accelerates chondrocyte maturation and Col10a1 expression in mice, whereas the expression of dominant negative (dn)-Runx2 in chondrocytes under the control of the Col2a1 promoter decelerates chondrocyte maturation and reduces Col10a1 expression in mice (Ueta et al. 2001 ). RUNX2 and RUNX3 have redundant functions in chondrocyte maturation, and chondrocyte maturation is completely inhibited in whole skeletons of Runx2 (Yoshida et al. 2004 ).
Hypertrophic chondrocytes expressing Col10a1 are absent in Runx2
In vitro analyses have shown that RUNX2 induces Col10a1 expression, and that RUNX2 directly regulates the Col10a1 promoter by using core responsive elements located at −2.4 kb in mouse and chicken and between −89 and −60 bp in humans (Enomoto et al. 2000; Zheng et al. 2003; Drissi et al. 2003; Higashikawa et al. 2009) (Fig. 1 TNC (tenascin-C) is expressed in chondrocytes once cartilage tissue appears, but its expression becomes limited to the articular chondrocytes as cartilage development progresses (Pacifici 1995) . In Runx2 transgenic mice under the control of the Col2a1 promoter, permanent cartilage enters the endochondral pathway, and TNC expression in the presumptive joint region is lost, whereas most chondrocytes in dn-Runx2 transgenic mice under the control of the Col2a1 promoter retain the expression of TNC. Therefore, suppression of Runx2 expression is required for the formation and maintenance of permanent cartilage (Ueta et al. 2001) (Fig. 1) . In osteoarthritis, however, RUNX2 is detected in the articular cartilage, and RUNX2 is colocalized with COL10A1 or MMP13 Kamekura et al. 2006 ).
RUNX2 regulates the expression of bone matrix protein genes in osteoblasts
As Runx2 −/− mice lack osteoblasts, the expression of bone matrix protein genes including Spp1, Ibsp, and Bglap is virtually absent in these mice (Komori et al. 1997; Inada et al. 1999) . In type II Runx2-specific knockout mice, the expression of Col1a1, Spp1, and Bglap is reduced (Xiao et al. 2005) . In accordance with the results of the in vivo studies, in vitro studies have demonstrated that RUNX2 is a positive regulator that can upregulate the expression of bone matrix protein genes including Col1a1, Spp1, Ibsp, Bglap, and Fn1 (fibronectin 1) (Ducy et al. 1997; Sato et al. 1998; Harada et al. 1999; Lee et al. 2000) . RUNX2 is involved in the transcriptional activation of many promoters including those of Col1a1, Col1a2, Spp1, and Bglap (Banerjee et al. 1997; Kern et al. 2001; Harada et al. 1999; Jiménez et al. 1999; Sato et al. 1998 ). However, Ibsp is an exception, because Ibsp expression is reduced by RUNX2 and HDAC3 in vitro, and RUNX2 represses Ibsp promoter activity (Lamour et al. 2007; Javed et al. 2001) . Further, expression of dn-Runx2 under the control of the Bglap promoter, which directs reporter gene expression to mature osteoblasts, results in osteopenia because of drastic reductions in the expression of genes encoding the main bone matrix proteins including COL1A1, COL1A2, SPP1, IBSP, and BGLAP (Ducy et al. 1999) . However, transgenic mice that overexpress Runx2 under the control of a 2.3-kb mouse Col1a1 promoter, which directs reporter gene expression to immature and mature osteoblasts, show osteopenia with multiple fractures Geoffroy et al. 2002; Kanatani et al. 2006) . Most of the osteoblasts of these mice exhibit less mature phenotypes, and the numbers of terminally differentiated osteoblasts, which strongly express Bglap, and of osteocytes are greatly diminished. As a result, in the osteoblasts of these mice, the expression of Col1a1, Alpl (alkaline phosphatase, liver/bone/kidney), Bglap, and Mmp13, all of which normally increase during osteoblast maturation, are reduced Geoffroy et al. 2002; Kanatani et al. 2006) , although the changes in the expression of the bone matrix protein genes could be, in part, attributable to the abnormal osteoblast differentiation in Runx2 transgenic mice. In dn-Runx2 transgenic mice under the control of the same 2.3-kb mouse Col1a1 promoter, the volume of the trabecular bone is increased, and the expression of major bone matrix protein genes including Col1a1, Spp1, and Bglap, is not significantly affected compared with those in wild-type mice, although dn-RUNX2 rescues the reduction of Bglap expression in the Runx2 transgenic mice (Maruyama et al. 2007 ). These findings, together with the in vitro data, indicate that RUNX2 induces the expression of major bone matrix protein genes in osteoblast progenitors, allowing the cells to acquire the osteoblastic phenotype while keeping the osteoblastic cells in an immature stage. As the expression patterns of Runx2 and Spp1 are similar during bone development, and as Spp1 expression is increased in Runx2 transgenic mice, RUNX2 is likely to maintain Spp1 expression in immature osteoblasts (Maruyama et al. 2007; Liu et al. 2001; Geoffroy et al. 2002; Kanatani et al. 2006) . In mature osteoblasts, a low level of Runx2 expression might nevertheless be required for the maintenance of the expression of Col1a1 and Bglap (Fig. 1) .
Osteoblast differentiation and bone maturation
In transgenic mice overexpressing Runx2 under the control of the 2.3-kb Col1a1 promoter, cortical bone has a woven bone-like structure, the cortical bone mass but not the trabecular bone mass is severely reduced, and the reduction in cortical bone mass is attributable to accelerated resorption caused by the increase in recruitment and activity of osteoclasts Geoffroy et al. 2002; Kanatani et al. 2006) . This seems to be caused by the immature composition of cortical bone, which contains abundant SPP1 with the small cell attachment motif (Arg-Gly-Asp [RGD]); the RGD is recognized by integrins and promotes the attachment of osteoclasts to the extracellular matrix (Young et al. 1993 ). The expression of IBSP, which also has the RGD motif, is increased in Runx2 transgenic mice under the control of the 2.3-kb Col1a1 promoter Geoffroy et al. 2002) and may also contribute to the accelerated resorption of cortical bone.
In contrast, the trabecular bone increases in volume without deceleration of osteoclastogenesis in adult dnRunx2 transgenic mice under the control of the 2.3-kb Col1a1 promoter (Maruyama et al. 2007 ). The extent of mineralization in the trabecular bone is higher in dn-Runx2 transgenic mice than in wild-type mice. Further, although the collagen fibrils are loosely deposited in a random orientation in the trabecular bone of wild-type mice, they are densely and regularly packed in the trabecular bone of dn-Runx2 transgenic mice. These characteristics of the trabecular bone of dn-Runx2 transgenic mice are similar to those seen in cortical bone, indicating that the trabecular bone in dn-Runx2 transgenic mice has characteristics of compact bone, which represents a more mature bone than trabecular bone and is more resistant to osteolysis. Thus, RUNX2 directs multipotent mesenchymal cells to the osteoblast lineage and triggers the expression of major bone matrix protein genes, leading to an increase in immature osteoblasts, which form immature bone. However, Runx2 expression has to be downregulated for the phenotype of fully mature osteoblasts, which form mature bone, to be acquired (Figs. 1, 2) .
Odontoblast differentiation and RUNX2
Endogenous Runx2 is expressed in preodontoblasts and is downregulated during odontoblast differentiation (Bronckers et al. 2001; Yamashiro et al. 2002; Chen et al. 2005; Miyazaki et al. 2008) (Fig. 2) Fig. 2 Regulation of osteoblast and odontoblast differentiation by RUNX2. RUNX2 directs pluripotent mesenchymal cells to the osteoblast lineage, increases the number of immature osteoblasts, but inhibits osteoblast maturation. Preosteoblasts express Runx2. Immature osteoblasts express Runx2 and Spp1 and, subsequently, Bglap. Mature osteoblasts express Bglap, but Runx2 expression is downregulated. Osteocytes express Dmp1. The transition of immature osteoblasts to osteocytes occurs at an early stage of bone development. The common precursors of osteoblasts and odontoblasts are restricted to neural-crest-derived mesenchymal cells, but the basal process of osteoblast differentiation is similar in the neural-crest-derived and non-neural-crest-derived pluripotent mesenchymal cells. Preodontoblasts differentiate from neural-crest-derived pluripotent mesenchymal cells. RUNX2 is essential for differentiation of pluripotent mesenchymal cells into preodontoblasts. RUNX2 also probably induces the differentiation of preodontoblasts into immature odontoblasts at an early stage but is inhibitory at a late stage. Preodontoblasts express Runx2, immature odontoblasts express Dspp and Nes but Runx2 weakly, and mature odontoblasts express Dspp and Nes but not Runx2. Runx2 expression is downregulated during odontoblast differentiation, and RUNX2 inhibits terminal differentiation of odontoblasts. Overexpression of Runx2 induced transdifferentiation of odontoblasts to osteoblasts (Spp1 secreted phophoprotein 1/osteopontin, Bglap bone gamma-carboxyglutamate [gla] protein/osteocalcin, Dspp dentin sialophosphoprotein, Nes nestin, Dmp1 dentin matrix protein 1) expression has been detected in odontoblasts and osteoblasts (Miyazaki et al. 2008) . The overexpression of Runx2 in odonotoblasts inhibits their terminal differentiation and induces the transdifferentiation of odontoblasts into osteoblasts, forming a bone structure (Miyazaki et al. 2008) . The gene expression of DSPP (dentin sialophosphoprotein), which is known to be a tooth-specific extracellular matrix protein (D'Souza et al. 1997; Begue-Kirn et al. 1998) , is severely downregulated in odontoblasts of Runx2 transgenic mice. Further, NES (nestin), which is an intermediate filament protein and an odontoblast marker protein that is not expressed in osteoblasts (Terling et al. 1995) , is also severely downregulated in the odontoblasts. The levels of SPP1 and DMP1, which are noncollagenous proteins present in both bone and teeth but with higher expression levels in the former (D'Souza et al. 1997; Aguiar and Arana-Chavez 2007) , are increased in the dentin of Runx2 transgenic mice. The mRNA of COL1A1, a major organic component of bone and dentin, is similarly expressed in immature odontoblasts of both wild-type and Runx2 transgenic mice; however, it decreases after transdifferentiation from odontoblasts to osteoblasts in Runx2 transgenic mice. The expression of BGLAP, another protein found in both bone and dentin, is upregulated in immature odontoblasts, but is also downregulated after transdifferentiation in Runx2 transgenic mice. Therefore, RUNX2 is able to alter the expression of extracellular matrix protein genes in odontoblasts and to induce the expression of bone matrix protein genes in odontoblasts, leading to their transdifferentiation to osteoblasts (Fig. 2) . After transdifferentiation into osteoblasts, however, the expression of Col1a1 and Bglap is downregulated, as has been observed in the osteoblasts of Runx2 transgenic mice Geffroy et al. 2002; Kanatani et al. 2006; Miyazaki et al. 2008) .
